{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "a9c55dcb-f09f-4ce3-afbc-1c0c762518b7",
   "metadata": {},
   "source": [
    "# 2022 (lst)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0a705ccb-151f-4244-abfd-7f96c630d256",
   "metadata": {
    "tags": [
     "hide-input"
    ]
   },
   "outputs": [
    {
     "data": {
      "text/markdown": [
       "There are 148 documents issued during the year of 2022. Below is a list of those documents."
      ],
      "text/plain": [
       "<IPython.core.display.Markdown object>"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from IPython.display import Markdown as md\n",
    "pd.set_option('display.max_rows', 200, 'display.max_colwidth', None)\n",
    "\n",
    "if(True):\n",
    "    import sys\n",
    "    sys.path.insert(0, '..')\n",
    "    import myutil.pdf2txt\n",
    "    myutil.pdf2txt.fxlsx2csv(\"../suppfiles/lstcurrent\")\n",
    "df=pd.read_csv(\"../suppfiles/lstcurrent.csv\")\n",
    "lst2=df.drop(['Unnamed: 0','Open for Comment'], axis=1).set_index(['Issue Date']).filter(regex='2022',axis=0).reset_index().drop(['Docket Number', 'Issue Date','Topic'], axis=1).set_index(['Issue Date0','Guidance Status'])\n",
    "\n",
    "md(\"There are \"+str(len(lst2))+\" documents issued during the year of 2022. Below is a list of those documents.\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "0597830d-3fc8-4ab7-ae29-33446b635dfb",
   "metadata": {
    "tags": [
     "hide-input"
    ]
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>Summary</th>\n",
       "      <th>FDA Organization</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Issue Date0</th>\n",
       "      <th>Guidance Status</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-09-07</th>\n",
       "      <th>Draft</th>\n",
       "      <td>General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Policy for Monkeypox Tests to Address the Public Health Emergency:  Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"5\" valign=\"top\">2022-08-26</th>\n",
       "      <th>Draft</th>\n",
       "      <td>E11A Pediatric Extrapolation</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>M12 Drug Interaction Studies</td>\n",
       "      <td>(CDER) ,Office of Regulatory Policy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Q14 Analytical Procedure Development</td>\n",
       "      <td>(CDER) ,Office of Regulatory Policy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Q2(R2) Validation of Analytical Procedures</td>\n",
       "      <td>(CDER) ,Office of Regulatory Policy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers :  Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-08-23</th>\n",
       "      <th>Final</th>\n",
       "      <td>Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies</td>\n",
       "      <td>(CTP)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Charging for Investigational Drugs Under an IND: Questions and Answers</td>\n",
       "      <td>(CDER) Office of the Commissioner,Office of Clinical Policy and Programs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"3\" valign=\"top\">2022-08-17</th>\n",
       "      <th>Final</th>\n",
       "      <td>Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-08-15</th>\n",
       "      <th>Final</th>\n",
       "      <td>FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"9\" valign=\"top\">2022-08-12</th>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics:  Specific Recommendations for Bovines</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics:  Specific Recommendations for Ovines</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics:  Specific Recommendations for Caprines</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-08-10</th>\n",
       "      <th>Final</th>\n",
       "      <td>CVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-08-05</th>\n",
       "      <th>Final</th>\n",
       "      <td>Bioresearch Monitoring Technical Conformance Guide</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-08-02</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-08-01</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Policy Regarding N-acetyl-L-cysteine</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-29</th>\n",
       "      <th>Final</th>\n",
       "      <td>Changes to Disposable Manufacturing Materials:  Questions and Answers Guidance for Industry</td>\n",
       "      <td>(CVM) (CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-28</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-07-27</th>\n",
       "      <th>Final</th>\n",
       "      <td>General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings:  Guidance for Industry</td>\n",
       "      <td>(OCE) (CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-25</th>\n",
       "      <th>Final</th>\n",
       "      <td>Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CBER) (CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"4\" valign=\"top\">2022-07-22</th>\n",
       "      <th>Final</th>\n",
       "      <td>Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry:  Guidance for Industry</td>\n",
       "      <td>(CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Orange Book Questions and Answers Guidance for Industry:  Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Conducting Remote Regulatory Assessments Questions and Answers: Draft Guidance for Industry</td>\n",
       "      <td>(ORA)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Real-Time Oncology Review (RTOR) : Draft Guidance for Industry</td>\n",
       "      <td>(OCE)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-07-21</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Evaluation of Therapeutic Equivalence</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”</td>\n",
       "      <td>(CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-18</th>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-15</th>\n",
       "      <th>Final</th>\n",
       "      <td>Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products — Content and Format</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-08</th>\n",
       "      <th>Final</th>\n",
       "      <td>CVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-06</th>\n",
       "      <th>Draft</th>\n",
       "      <td>DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-05</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Identifying Trading Partners Under the Drug Supply Chain Security Act</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-07-01</th>\n",
       "      <th>Final</th>\n",
       "      <td>CVM GFI #108 Registering with CVM’s Electronic Submission System</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-06-29</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-06-28</th>\n",
       "      <th>Final</th>\n",
       "      <td>Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry</td>\n",
       "      <td>(OCE) (CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-06-27</th>\n",
       "      <th>Final</th>\n",
       "      <td>Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry</td>\n",
       "      <td>(OCE) (CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Draft Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"4\" valign=\"top\">2022-06-24</th>\n",
       "      <th>Final</th>\n",
       "      <td>Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Considerations for Rescinding Breakthrough Therapy Designation</td>\n",
       "      <td>(CDER) (CBER) (OCE)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry</td>\n",
       "      <td>(CDER) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-06-21</th>\n",
       "      <th>Final</th>\n",
       "      <td>FDA Oversight of Food Covered by Systems Recognition Arrangements</td>\n",
       "      <td>(ORA)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures: Draft Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-06-16</th>\n",
       "      <th>Final</th>\n",
       "      <td>Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-06-15</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies: Draft Guidance for Industry</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-06-14</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Q9(R1) Quality Risk Management</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-06-06</th>\n",
       "      <th>Final</th>\n",
       "      <td>Electromagnetic Compatibility (EMC) of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-06-01</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Fish and Fishery Products Hazards and Controls</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-05-27</th>\n",
       "      <th>Final</th>\n",
       "      <td>Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry:  Clinical/Medical</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-05-25</th>\n",
       "      <th>Final</th>\n",
       "      <td>Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide</td>\n",
       "      <td>(ORA)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-05-24</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases – Questions and Answers (Revision 1)</td>\n",
       "      <td>(CDER) ,Office of New Drugs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"3\" valign=\"top\">2022-05-23</th>\n",
       "      <th>Final</th>\n",
       "      <td>Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components:  Guidance for Industry</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Draft Guidance for Industry</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Draft Guidance for Industry</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-05-19</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification</td>\n",
       "      <td>(CFSAN) ,Office of Dietary Supplement Programs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Risk Management Plans to Mitigate the Potential for Drug Shortages</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-05-18</th>\n",
       "      <th>Final</th>\n",
       "      <td>Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-05-17</th>\n",
       "      <th>Final</th>\n",
       "      <td>Assessing User Fees Under the Generic Drug User Fee Amendments of 2017</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-05-16</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Infant Formula Enforcement Discretion Policy</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision:  Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-05-13</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-05-10</th>\n",
       "      <th>Final</th>\n",
       "      <td>CVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-05-09</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Benefit-Risk Considerations for Product Quality Assessments</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-05-06</th>\n",
       "      <th>Final</th>\n",
       "      <td>Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program: Draft Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-05-04</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised):  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CBER) (CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-05-02</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability</td>\n",
       "      <td>(OCE)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"3\" valign=\"top\">2022-04-29</th>\n",
       "      <th>Final</th>\n",
       "      <td>E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide —Appendix to the Implementation Guide — Backwards and Forwards Compatibility</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Electronic Submission of IND Safety Reports Technical Conformance Guide :  Guidance for Industry</td>\n",
       "      <td>(CDER) (OCE) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"3\" valign=\"top\">2022-04-28</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Crohn’s Disease:  Developing Drugs for Treatment</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Draft Guidance for Industry: The Accredited Third-Party Certification Program: Questions and Answers</td>\n",
       "      <td>(CVM) (ORA) (CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Ulcerative Colitis:  Developing Drugs for Treatment</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"3\" valign=\"top\">2022-04-27</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation</td>\n",
       "      <td>(CVM) (CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Providing Submissions in Electronic Format — Postmarketing Safety Reports</td>\n",
       "      <td>(CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Draft Guidance for Industry: Action Levels for Lead in Juice</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-04-21</th>\n",
       "      <th>Final</th>\n",
       "      <td>Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Refuse to Accept Policy for 510(k)s:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-04-20</th>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-04-18</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Draft Guidance for FDA Staff and Stakeholders: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-04-15</th>\n",
       "      <th>Final</th>\n",
       "      <td>Bioavailability Studies Submitted in NDAs or INDs – General Considerations</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet</td>\n",
       "      <td>(CDER) ,Office of New Drugs(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-04-14</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Draft Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"4\" valign=\"top\">2022-04-13</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Reconditioning of Fish and Fishery Products by Segregation</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability: Draft Guidance for Industry</td>\n",
       "      <td>(OCE) (CDER) (CBER) (CDRH) Office of the Commissioner,Office of Minority Health and Health Equity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Denture Base Resins - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Facet Screw Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"3\" valign=\"top\">2022-04-11</th>\n",
       "      <th>Final</th>\n",
       "      <td>Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs</td>\n",
       "      <td>(CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Orthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Surgical Sutures - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-04-08</th>\n",
       "      <th>Final</th>\n",
       "      <td>E8(R1) General Considerations for Clinical Studies</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions: Draft Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-04-07</th>\n",
       "      <th>Final</th>\n",
       "      <td>Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers: Draft Guidance for Industry</td>\n",
       "      <td>(CDER) (CBER) (CDRH) (CFSAN) (CTP) (ORA) (CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-04-06</th>\n",
       "      <th>Draft</th>\n",
       "      <td>M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES: Draft Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-03-31</th>\n",
       "      <th>Final</th>\n",
       "      <td>Emergency Use Authorization for Vaccines to Prevent COVID-19:  Guidance for Industry</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-03-22</th>\n",
       "      <th>Final</th>\n",
       "      <td>An Acceptable Circular of Information for the Use of Human Blood and Blood Components:  Guidance for Industry</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4  Guidance for Industry:  Guidance for Industry</td>\n",
       "      <td>(CBER) (CDRH) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-03-15</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Human Gene Therapy Products Incorporating Human Genome Editing</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-03-11</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions</td>\n",
       "      <td>(CFSAN) (CVM) (ORA)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-03-09</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs: Draft Guidance for Industry</td>\n",
       "      <td>(CDER) ,Office of Regulatory Policy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-03-04</th>\n",
       "      <th>Final</th>\n",
       "      <td>Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C:  Guidance for Industry and FDA Staff</td>\n",
       "      <td>(CVM) (ORA) (CFSAN) (CBER) (CDRH) (CDER) (CTP)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"4\" valign=\"top\">2022-03-02</th>\n",
       "      <th>Draft</th>\n",
       "      <td>CVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Inclusion of Older Adults in Cancer Clinical Trials:  Guidance for Industry</td>\n",
       "      <td>(OCE) (CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Center for Devices and Radiological Health (CDRH) Appeals Processes:  Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Physician Notification Orders:  Guidance for Mammography Facilities and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"4\" valign=\"top\">2022-03-01</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: FDA's Voluntary Qualified Importer Program</td>\n",
       "      <td>(CVM) (ORA) (CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry</td>\n",
       "      <td>(CDER) (CBER) (OCE)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Master Protocols:  Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry</td>\n",
       "      <td>(OCE) (CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Pre-Launch Activities Importation Requests (PLAIR):  Guidance for Industry</td>\n",
       "      <td>Office of the Commissioner(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-02-25</th>\n",
       "      <th>Final</th>\n",
       "      <td>Patient-Focused Drug Development: Methods to Identify What Is Important to Patients:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-02-24</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">2022-02-09</th>\n",
       "      <th>Final</th>\n",
       "      <td>Guidance for Industry: Questions and Answers Regarding Channels of Trade Policy for Human Food Commodities with Chlorpyrifos Residues</td>\n",
       "      <td>(CFSAN)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry: Draft Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-02-08</th>\n",
       "      <th>Final</th>\n",
       "      <td>COVID-19 Public Health Emergency Policy on COVID-19-Related Sanitation Tunnels:  Guidance for Industry and Investigators</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-02-07</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry: Draft Guidance for Industry</td>\n",
       "      <td>(CDER) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-02-04</th>\n",
       "      <th>Final</th>\n",
       "      <td>Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic:  Guidance for Industry</td>\n",
       "      <td>(OCE) (CBER) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"4\" valign=\"top\">2022-02-03</th>\n",
       "      <th>Final</th>\n",
       "      <td>Drug Product Tracing: The Effect of Section 585 of the FD&amp;C Act</td>\n",
       "      <td>(CDER) (CBER) (ORA)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Population Pharmacokinetics:  Guidance for Industry</td>\n",
       "      <td>(CDER) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry</td>\n",
       "      <td>(CDER) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-02-01</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs</td>\n",
       "      <td>(CDER) ,Office of New Drugs</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"5\" valign=\"top\">2022-01-26</th>\n",
       "      <th>Final</th>\n",
       "      <td>Good ANDA Submission Practices Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry</td>\n",
       "      <td>(CDER) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Principles of Premarket Pathways for Combination Products:  Guidance for Industry and FDA Staff</td>\n",
       "      <td>(CBER) (CDRH) (CDER) Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation:  Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders</td>\n",
       "      <td>(CDRH) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Patient Engagement in the Design and Conduct of Medical Device Clinical Studies:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders</td>\n",
       "      <td>(CDRH) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-01-25</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Revising ANDA  Labeling Following  Revision of the RLD  Labeling Guidance for Industry: Draft Guidance for Industry</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"3\" valign=\"top\">2022-01-21</th>\n",
       "      <th>Final</th>\n",
       "      <td>CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI</td>\n",
       "      <td>(CVM)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Final</th>\n",
       "      <td>Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH):  Guidance for Industry Technical Specifications Document</td>\n",
       "      <td>(CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Draft</th>\n",
       "      <td>Digital Health Technologies for Remote Data Acquisition in Clinical Investigations: Draft Guidance for Industry, Investigators, and Other Stakeholders</td>\n",
       "      <td>(OCE) (CBER) (CDRH) (CDER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-01-11</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&amp;C Act: Draft Guidance for Industry and Food and Drug Administration Staff</td>\n",
       "      <td>(CDRH) (CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-01-07</th>\n",
       "      <th>Final</th>\n",
       "      <td>Investigational COVID-19 Convalescent Plasma:  Guidance for Industry</td>\n",
       "      <td>(CBER)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2022-01-01</th>\n",
       "      <th>Draft</th>\n",
       "      <td>Collecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry</td>\n",
       "      <td>(CDER) (CVM) (ORA) (CBER) (CFSAN)</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                            Summary  \\\n",
       "Issue Date0 Guidance Status                                                                                                                                                                                                                                                                           \n",
       "2022-09-07  Draft                                                                                                                                                                        General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products   \n",
       "            Final                                                                                                                    Policy for Monkeypox Tests to Address the Public Health Emergency:  Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff   \n",
       "2022-08-26  Draft                                                                                                                                                                                                                                                      E11A Pediatric Extrapolation   \n",
       "            Draft                                                                                                                                                                                                                                                      M12 Drug Interaction Studies   \n",
       "            Draft                                                                                                                                                                                                                                              Q14 Analytical Procedure Development   \n",
       "            Draft                                                                                                                                                                                                                                        Q2(R2) Validation of Analytical Procedures   \n",
       "            Final                                                                                                                       E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers :  Guidance for Industry   \n",
       "2022-08-23  Final                                                                                                                                                                        Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies   \n",
       "            Draft                                                                                                                                                                                                            Charging for Investigational Drugs Under an IND: Questions and Answers   \n",
       "2022-08-17  Final                                                                                                                          Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "            Final                                                                                                                                                            Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff   \n",
       "            Draft                                                                           Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-08-15  Final                                                                                                                                          FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products   \n",
       "2022-08-12  Draft                                                                                                                                                                                     CVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines   \n",
       "            Draft                                                                                                                                                                                    CVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines   \n",
       "            Draft                                                                                                                                                                                     CVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines   \n",
       "            Draft                                                                                                                                                                                     CVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines   \n",
       "            Draft                                                                                                                                                                      CVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus   \n",
       "            Draft                                                                                                                                                                                                    CVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations   \n",
       "            Draft                                                                                                                                                                                     CVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics:  Specific Recommendations for Bovines   \n",
       "            Draft                                                                                                                                                                                      CVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics:  Specific Recommendations for Ovines   \n",
       "            Draft                                                                                                                                                                                    CVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics:  Specific Recommendations for Caprines   \n",
       "2022-08-10  Final                                                                                                                                                                                                                 CVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances   \n",
       "            Final                                                  Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)   \n",
       "2022-08-05  Final                                                                                                                                                                                                                                Bioresearch Monitoring Technical Conformance Guide   \n",
       "2022-08-02  Draft                                                                                                                                                                             Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry   \n",
       "2022-08-01  Final                                                                                                                                                                                                                       Guidance for Industry: Policy Regarding N-acetyl-L-cysteine   \n",
       "2022-07-29  Final                                                                                                                                                                                       Changes to Disposable Manufacturing Materials:  Questions and Answers Guidance for Industry   \n",
       "2022-07-28  Draft                                                                                                                       Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-07-27  Final                                                                                                                                                         General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry   \n",
       "            Final                                                                                                                                                                    Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings:  Guidance for Industry   \n",
       "2022-07-25  Final            Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-07-22  Final                                                                                                                                              Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry:  Guidance for Industry   \n",
       "            Final                                                                                                                                                                                                   Orange Book Questions and Answers Guidance for Industry:  Guidance for Industry   \n",
       "            Draft                                                                                                                                                                                       Conducting Remote Regulatory Assessments Questions and Answers: Draft Guidance for Industry   \n",
       "            Draft                                                                                                                                                                                                                    Real-Time Oncology Review (RTOR) : Draft Guidance for Industry   \n",
       "2022-07-21  Draft                                                                                                                                                                                                                                             Evaluation of Therapeutic Equivalence   \n",
       "            Draft                                                                                                                             Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”   \n",
       "2022-07-18  Draft                                                                                                                                   CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)   \n",
       "2022-07-15  Final                                                                                                                                                                  Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products — Content and Format   \n",
       "2022-07-08  Final                                                                                                                                                                                              CVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals   \n",
       "2022-07-06  Draft                                                                                                                                    DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry   \n",
       "2022-07-05  Draft                                                                                                                                                                                                             Identifying Trading Partners Under the Drug Supply Chain Security Act   \n",
       "2022-07-01  Final                                                                                                                                                                                                                  CVM GFI #108 Registering with CVM’s Electronic Submission System   \n",
       "2022-06-29  Draft                                                                                                                                                                Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments   \n",
       "2022-06-28  Final                                                                                                                                                                                     Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry   \n",
       "2022-06-27  Final                                                                                                                                                                               Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry   \n",
       "            Draft                                                                                                                                                             Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Draft Guidance for Industry   \n",
       "2022-06-24  Final                                                                                                                                                                                    Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations   \n",
       "            Draft                                                                                                                                                                                                                    Considerations for Rescinding Breakthrough Therapy Designation   \n",
       "            Final                                                                                                                                                                     Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry   \n",
       "            Draft                                                                                                                                                               Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry   \n",
       "2022-06-21  Final                                                                                                                                                                                                                 FDA Oversight of Food Covered by Systems Recognition Arrangements   \n",
       "            Draft                                                                                                   Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures: Draft Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-06-16  Final                                                                                                              Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-06-15  Draft                                                                                                                                                                Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies: Draft Guidance for Industry   \n",
       "2022-06-14  Draft                                                                                                                                                                                                                                                    Q9(R1) Quality Risk Management   \n",
       "2022-06-06  Final                                                                                                                                                             Electromagnetic Compatibility (EMC) of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-06-01  Final                                                                                                                                                                                                             Guidance for Industry: Fish and Fishery Products Hazards and Controls   \n",
       "2022-05-27  Final                                                                                                                                                            Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry:  Clinical/Medical   \n",
       "2022-05-25  Final                                                                                                                                                                                 Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide   \n",
       "2022-05-24  Draft                                                                                                                              Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases – Questions and Answers (Revision 1)   \n",
       "2022-05-23  Final                                                                                              Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components:  Guidance for Industry   \n",
       "            Draft                                                                                                                                                                          Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Draft Guidance for Industry   \n",
       "            Draft                                                                                                         Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Draft Guidance for Industry   \n",
       "2022-05-19  Draft                                                                                                                      Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification   \n",
       "            Draft                                                                                                                                                                                                                Risk Management Plans to Mitigate the Potential for Drug Shortages   \n",
       "2022-05-18  Final                                                                                                                                                                               Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors   \n",
       "2022-05-17  Final                                                                                                                                                                                                            Assessing User Fees Under the Generic Drug User Fee Amendments of 2017   \n",
       "2022-05-16  Final                                                                                                                                                                                                               Guidance for Industry: Infant Formula Enforcement Discretion Policy   \n",
       "            Final                                                                                                                                                    Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision:  Guidance for Industry   \n",
       "2022-05-13  Final                                                                                                                                                                             Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting   \n",
       "2022-05-10  Final                                                                                                                                                             CVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals   \n",
       "            Draft                                                                                                                                                                                         CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover   \n",
       "2022-05-09  Draft                                                                                                                                                                                                                       Benefit-Risk Considerations for Product Quality Assessments   \n",
       "2022-05-06  Final                                      Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "            Draft                                                                                                    Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program: Draft Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-05-04  Draft                                                                                                                                                                                                  Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies   \n",
       "            Final                              Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised):  Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-05-02  Draft                                                                                                                                            Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability   \n",
       "2022-04-29  Final                                                                 E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility   \n",
       "            Final                                                                                                           E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide —Appendix to the Implementation Guide — Backwards and Forwards Compatibility   \n",
       "            Final                                                                                                                                                                                  Electronic Submission of IND Safety Reports Technical Conformance Guide :  Guidance for Industry   \n",
       "2022-04-28  Draft                                                                                                                                                                                                                                  Crohn’s Disease:  Developing Drugs for Treatment   \n",
       "            Draft                                                                                                                                                                              Draft Guidance for Industry: The Accredited Third-Party Certification Program: Questions and Answers   \n",
       "            Draft                                                                                                                                                                                                                               Ulcerative Colitis:  Developing Drugs for Treatment   \n",
       "2022-04-27  Final                                                                                                            Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation   \n",
       "            Final                                                                                                                                                                                                         Providing Submissions in Electronic Format — Postmarketing Safety Reports   \n",
       "            Draft                                                                                                                                                                                                                      Draft Guidance for Industry: Action Levels for Lead in Juice   \n",
       "2022-04-21  Final                                                                                                                                                                                  Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry   \n",
       "            Final                                                                                                                                                                                Refuse to Accept Policy for 510(k)s:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-04-20  Draft                                                                                                                                                                                              CVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals   \n",
       "2022-04-18  Draft                                                                                   Draft Guidance for FDA Staff and Stakeholders: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act   \n",
       "2022-04-15  Final                                                                                                                                                                                                        Bioavailability Studies Submitted in NDAs or INDs – General Considerations   \n",
       "            Draft                                                                                                                                                                                                   Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet   \n",
       "2022-04-14  Draft                                                                                                                        Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Draft Guidance for Industry   \n",
       "2022-04-13  Final                                                                                                                                                                                                 Guidance for Industry: Reconditioning of Fish and Fishery Products by Segregation   \n",
       "            Draft                                                                              Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability: Draft Guidance for Industry   \n",
       "            Final                                                                                                                                Denture Base Resins - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "            Final                                                                                                                                Facet Screw Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-04-11  Final                                                                                                                              Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs   \n",
       "            Final                                                                                                                Orthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "            Final                                                                                                                                   Surgical Sutures - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-04-08  Final                                                                                                                                                                                                                                E8(R1) General Considerations for Clinical Studies   \n",
       "            Draft                                                                                                          Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions: Draft Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-04-07  Final                                                                                                                                                                                                               Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment   \n",
       "            Draft                                                                                                                                                                  Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers: Draft Guidance for Industry   \n",
       "2022-04-06  Draft                                                                                                                        M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES: Draft Guidance for Industry   \n",
       "2022-03-31  Final                                                                                                                                                                                              Emergency Use Authorization for Vaccines to Prevent COVID-19:  Guidance for Industry   \n",
       "2022-03-22  Final                                                                                                                                                                     An Acceptable Circular of Information for the Use of Human Blood and Blood Components:  Guidance for Industry   \n",
       "            Final                                                                                                                                                        Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4  Guidance for Industry:  Guidance for Industry   \n",
       "2022-03-15  Draft                                                                                                                                                                                             Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products   \n",
       "            Draft                                                                                                                                                                                                                    Human Gene Therapy Products Incorporating Human Genome Editing   \n",
       "2022-03-11  Final                                             Guidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions   \n",
       "2022-03-09  Draft                                                                                                                                                         Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs: Draft Guidance for Industry   \n",
       "2022-03-04  Final                                                                                                                                                                              Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C:  Guidance for Industry and FDA Staff   \n",
       "2022-03-02  Draft                                                                                                                                                                                        CVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds   \n",
       "            Final                                                                                                                                                                                                       Inclusion of Older Adults in Cancer Clinical Trials:  Guidance for Industry   \n",
       "            Final                                                                                                                                                Center for Devices and Radiological Health (CDRH) Appeals Processes:  Guidance for Industry and Food and Drug Administration Staff   \n",
       "            Final                   Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Physician Notification Orders:  Guidance for Mammography Facilities and Food and Drug Administration Staff   \n",
       "2022-03-01  Final                                                                                                                                                                                                                 Guidance for Industry: FDA's Voluntary Qualified Importer Program   \n",
       "            Final                                                                                                                    Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry   \n",
       "            Final                                                                                                               Master Protocols:  Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry   \n",
       "            Final                                                                                                                                                                                                        Pre-Launch Activities Importation Requests (PLAIR):  Guidance for Industry   \n",
       "2022-02-25  Final                                                                                                           Patient-Focused Drug Development: Methods to Identify What Is Important to Patients:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders   \n",
       "2022-02-24  Final                                                                                                                                        Guidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits   \n",
       "2022-02-09  Final                                                                                                                                             Guidance for Industry: Questions and Answers Regarding Channels of Trade Policy for Human Food Commodities with Chlorpyrifos Residues   \n",
       "            Draft                                                                                                                                                                     Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry: Draft Guidance for Industry   \n",
       "2022-02-08  Final                                                                                                                                                          COVID-19 Public Health Emergency Policy on COVID-19-Related Sanitation Tunnels:  Guidance for Industry and Investigators   \n",
       "2022-02-07  Draft                                                                                                                                                             Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry: Draft Guidance for Industry   \n",
       "2022-02-04  Final                                                                                                                                          Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic:  Guidance for Industry   \n",
       "2022-02-03  Final                                                                                                                                                                                                                   Drug Product Tracing: The Effect of Section 585 of the FD&C Act   \n",
       "            Final                                                                                                                                                                                                                               Population Pharmacokinetics:  Guidance for Industry   \n",
       "            Draft                                                                                                                                                                                         Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry   \n",
       "            Draft                                                                                                                            Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry   \n",
       "2022-02-01  Draft                                                                                                                                                           Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs   \n",
       "2022-01-26  Final                                                                                                                                                                                                                              Good ANDA Submission Practices Guidance for Industry   \n",
       "            Final                                                                                                                                                             Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry   \n",
       "            Final                                                                                                                                                                                   Principles of Premarket Pathways for Combination Products:  Guidance for Industry and FDA Staff   \n",
       "            Final                                                    Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation:  Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders   \n",
       "            Final                                                                                                               Patient Engagement in the Design and Conduct of Medical Device Clinical Studies:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders   \n",
       "2022-01-25  Draft                                                                                                                                                               Revising ANDA  Labeling Following  Revision of the RLD  Labeling Guidance for Industry: Draft Guidance for Industry   \n",
       "2022-01-21  Final                                                                                                                        CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI   \n",
       "            Final                                                                                      Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH):  Guidance for Industry Technical Specifications Document   \n",
       "            Draft                                                                                                                            Digital Health Technologies for Remote Data Acquisition in Clinical Investigations: Draft Guidance for Industry, Investigators, and Other Stakeholders   \n",
       "2022-01-11  Draft                                                                                   Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act: Draft Guidance for Industry and Food and Drug Administration Staff   \n",
       "2022-01-07  Final                                                                                                                                                                                                              Investigational COVID-19 Convalescent Plasma:  Guidance for Industry   \n",
       "2022-01-01  Draft                                                                                                                                                                                     Collecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry   \n",
       "\n",
       "                                                                                                                                  FDA Organization  \n",
       "Issue Date0 Guidance Status                                                                                                                         \n",
       "2022-09-07  Draft                                                                                                                          (CDER)   \n",
       "            Final                                                                                                                          (CDRH)   \n",
       "2022-08-26  Draft                                                                                                                          (CDER)   \n",
       "            Draft                                                                                              (CDER) ,Office of Regulatory Policy  \n",
       "            Draft                                                                                              (CDER) ,Office of Regulatory Policy  \n",
       "            Draft                                                                                              (CDER) ,Office of Regulatory Policy  \n",
       "            Final                                                                                                                          (CDER)   \n",
       "2022-08-23  Final                                                                                                                           (CTP)   \n",
       "            Draft                                                         (CDER) Office of the Commissioner,Office of Clinical Policy and Programs  \n",
       "2022-08-17  Final                                                                                                                          (CDRH)   \n",
       "            Final                                                                                                                          (CDRH)   \n",
       "            Draft                                                                                                                          (CDRH)   \n",
       "2022-08-15  Final                                                                                                                          (CDER)   \n",
       "2022-08-12  Draft                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "2022-08-10  Final                                                                                                                           (CVM)   \n",
       "            Final                                                                                                                         (CFSAN)   \n",
       "2022-08-05  Final                                                                                                                          (CDER)   \n",
       "2022-08-02  Draft                                                                                                                          (CDER)   \n",
       "2022-08-01  Final                                                                                                                         (CFSAN)   \n",
       "2022-07-29  Final                                                                                                             (CVM) (CBER) (CDER)   \n",
       "2022-07-28  Draft                                                                                                                          (CDRH)   \n",
       "2022-07-27  Final                                                                                                                          (CDER)   \n",
       "            Final                                                                                                             (OCE) (CBER) (CDER)   \n",
       "2022-07-25  Final                                                                                                                   (CBER) (CDRH)   \n",
       "2022-07-22  Final                                                                                                                   (CBER) (CDER)   \n",
       "            Final                                                                                                                          (CDER)   \n",
       "            Draft                                                                                                                           (ORA)   \n",
       "            Draft                                                                                                                           (OCE)   \n",
       "2022-07-21  Draft                                                                                                                          (CDER)   \n",
       "            Draft                                                                                                                   (CBER) (CDER)   \n",
       "2022-07-18  Draft                                                                                                                           (CVM)   \n",
       "2022-07-15  Final                                                                                                                          (CBER)   \n",
       "2022-07-08  Final                                                                                                                           (CVM)   \n",
       "2022-07-06  Draft                                                                                                                          (CDER)   \n",
       "2022-07-05  Draft                                                                                                                          (CDER)   \n",
       "2022-07-01  Final                                                                                                                           (CVM)   \n",
       "2022-06-29  Draft                                                                                                                          (CDER)   \n",
       "2022-06-28  Final                                                                                                             (OCE) (CBER) (CDER)   \n",
       "2022-06-27  Final                                                                                                             (OCE) (CBER) (CDER)   \n",
       "            Draft                                                                                                                          (CDER)   \n",
       "2022-06-24  Final                                                                                                                          (CDER)   \n",
       "            Draft                                                                                                             (CDER) (CBER) (OCE)   \n",
       "            Final                                                                                                                   (CDER) (CBER)   \n",
       "            Draft                                                                                                                          (CDER)   \n",
       "2022-06-21  Final                                                                                                                           (ORA)   \n",
       "            Draft                                                                                                                          (CDRH)   \n",
       "2022-06-16  Final                                                                                                                          (CDRH)   \n",
       "2022-06-15  Draft                                                                                                                          (CBER)   \n",
       "2022-06-14  Draft                                                                                                                          (CDER)   \n",
       "2022-06-06  Final                                                                                                                   (CDRH) (CBER)   \n",
       "2022-06-01  Final                                                                                                                         (CFSAN)   \n",
       "2022-05-27  Final                                                                                                                          (CDER)   \n",
       "2022-05-25  Final                                                                                                                           (ORA)   \n",
       "2022-05-24  Draft                                                                                                      (CDER) ,Office of New Drugs  \n",
       "2022-05-23  Final                                                                                                                          (CBER)   \n",
       "            Draft                                                                                                                          (CBER)   \n",
       "            Draft                                                                                                                          (CBER)   \n",
       "2022-05-19  Draft                                                                                   (CFSAN) ,Office of Dietary Supplement Programs  \n",
       "            Draft                                                                                                                          (CDER)   \n",
       "2022-05-18  Final                                                                                                                          (CDER)   \n",
       "2022-05-17  Final                                                                                                                          (CDER)   \n",
       "2022-05-16  Final                                                                                                                         (CFSAN)   \n",
       "            Final                                                                                                                          (CDER)   \n",
       "2022-05-13  Final                                                                                                                         (CFSAN)   \n",
       "2022-05-10  Final                                                                                                                           (CVM)   \n",
       "            Draft                                                                                                                           (CVM)   \n",
       "2022-05-09  Draft                                                                                                                          (CDER)   \n",
       "2022-05-06  Final                                                                                                                          (CDRH)   \n",
       "            Draft                                                                                                                          (CDRH)   \n",
       "2022-05-04  Draft                                                                                                                          (CDER)   \n",
       "            Final                                                                                                                   (CBER) (CDRH)   \n",
       "2022-05-02  Draft                                                                                                                           (OCE)   \n",
       "2022-04-29  Final                                                                                                                          (CDER)   \n",
       "            Final                                                                                                                          (CDER)   \n",
       "            Final                                                                                                             (CDER) (OCE) (CBER)   \n",
       "2022-04-28  Draft                                                                                                                          (CDER)   \n",
       "            Draft                                                                                                             (CVM) (ORA) (CFSAN)   \n",
       "            Draft                                                                                                                          (CDER)   \n",
       "2022-04-27  Final                                                                                                                   (CVM) (CFSAN)   \n",
       "            Final                                                                                                                   (CBER) (CDER)   \n",
       "            Draft                                                                                                                         (CFSAN)   \n",
       "2022-04-21  Final                                                                                                                          (CDER)   \n",
       "            Final                                                                                                                   (CDRH) (CBER)   \n",
       "2022-04-20  Draft                                                                                                                           (CVM)   \n",
       "2022-04-18  Draft                                                                                                                         (CFSAN)   \n",
       "2022-04-15  Final                                                                                                                          (CDER)   \n",
       "            Draft                                                                                               (CDER) ,Office of New Drugs(CBER)   \n",
       "2022-04-14  Draft                                                                                                                          (CDER)   \n",
       "2022-04-13  Final                                                                                                                         (CFSAN)   \n",
       "            Draft                                (OCE) (CDER) (CBER) (CDRH) Office of the Commissioner,Office of Minority Health and Health Equity  \n",
       "            Final                                                                                                                          (CDRH)   \n",
       "            Final                                                                                                                          (CDRH)   \n",
       "2022-04-11  Final                                                                                                                   (CBER) (CDER)   \n",
       "            Final                                                                                                                          (CDRH)   \n",
       "            Final                                                                                                                          (CDRH)   \n",
       "2022-04-08  Final                                                                                                                          (CDER)   \n",
       "            Draft                                                                                                                   (CDRH) (CBER)   \n",
       "2022-04-07  Final                                                                                                                          (CDER)   \n",
       "            Draft                                                                                  (CDER) (CBER) (CDRH) (CFSAN) (CTP) (ORA) (CVM)   \n",
       "2022-04-06  Draft                                                                                                                          (CDER)   \n",
       "2022-03-31  Final                                                                                                                          (CBER)   \n",
       "2022-03-22  Final                                                                                                                          (CBER)   \n",
       "            Final                                                                                                            (CBER) (CDRH) (CDER)   \n",
       "2022-03-15  Draft                                                                                                                          (CBER)   \n",
       "            Draft                                                                                                                          (CBER)   \n",
       "2022-03-11  Final                                                                                                             (CFSAN) (CVM) (ORA)   \n",
       "2022-03-09  Draft                                                                                              (CDER) ,Office of Regulatory Policy  \n",
       "2022-03-04  Final                                                                                  (CVM) (ORA) (CFSAN) (CBER) (CDRH) (CDER) (CTP)   \n",
       "2022-03-02  Draft                                                                                                                           (CVM)   \n",
       "            Final                                                                                                             (OCE) (CBER) (CDER)   \n",
       "            Final                                                                                                                          (CDRH)   \n",
       "            Final                                                                                                                          (CDRH)   \n",
       "2022-03-01  Final                                                                                                             (CVM) (ORA) (CFSAN)   \n",
       "            Final                                                                                                             (CDER) (CBER) (OCE)   \n",
       "            Final                                                                                                             (OCE) (CBER) (CDER)   \n",
       "            Final                                                                                                Office of the Commissioner(CDER)   \n",
       "2022-02-25  Final                                                                                                                          (CDER)   \n",
       "2022-02-24  Final                                                                                                                         (CFSAN)   \n",
       "2022-02-09  Final                                                                                                                         (CFSAN)   \n",
       "            Draft                                                                                                                          (CDER)   \n",
       "2022-02-08  Final                                                                                                                          (CDER)   \n",
       "2022-02-07  Draft                                                                                                                   (CDER) (CBER)   \n",
       "2022-02-04  Final                                                                                                             (OCE) (CBER) (CDER)   \n",
       "2022-02-03  Final                                                                                                             (CDER) (CBER) (ORA)   \n",
       "            Final                                                                                                                   (CDER) (CBER)   \n",
       "            Draft                                                                                                                          (CDER)   \n",
       "            Draft                                                                                                                   (CDER) (CBER)   \n",
       "2022-02-01  Draft                                                                                                      (CDER) ,Office of New Drugs  \n",
       "2022-01-26  Final                                                                                                                          (CDER)   \n",
       "            Final                                                                                                                   (CDER) (CBER)   \n",
       "            Final            (CBER) (CDRH) (CDER) Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products  \n",
       "            Final                                                                                                                   (CDRH) (CBER)   \n",
       "            Final                                                                                                                   (CDRH) (CBER)   \n",
       "2022-01-25  Draft                                                                                                                          (CDER)   \n",
       "2022-01-21  Final                                                                                                                           (CVM)   \n",
       "            Final                                                                                                                          (CDER)   \n",
       "            Draft                                                                                                      (OCE) (CBER) (CDRH) (CDER)   \n",
       "2022-01-11  Draft                                                                                                                   (CDRH) (CBER)   \n",
       "2022-01-07  Final                                                                                                                          (CBER)   \n",
       "2022-01-01  Draft                                                                                               (CDER) (CVM) (ORA) (CBER) (CFSAN)   "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lst2"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "P3_nbenv",
   "language": "python",
   "name": "nbenv"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
